Delisting, Listing Rule Failure, or Listing Transfer

Business Context and Reporting Period

This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) on September 16, 2019. The registrant is a Nevada corporation with its principal executive offices in Richmond, California. The report addresses a regulatory notice regarding the continued listing of its common stock on the Nasdaq Capital Market under the symbol "EKSO".

Key Financial Metrics

The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses exclusively on compliance with listing standards rather than financial performance metrics.

Material Changes

The material event reported is the receipt of a Deficiency Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC. The notice states that the Company's common stock closing bid price was below $1.00 per share for 30 consecutive business days, failing to meet the minimum closing bid price requirement under Rule 5550(a)(2) of the Nasdaq Listing Rules.

Guidance, Outlook, and Risks

  • Compliance Period: The Company has 180 calendar days (until March 16, 2020) to regain compliance. To do so, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days prior to the expiration of this period.
  • Future Actions: If compliance is not met by March 16, 2020, the Company may be eligible for a second 180-day compliance period, provided it meets other listing requirements (such as market value of publicly held shares) and notifies Nasdaq of its intent to cure the deficiency, potentially via a reverse stock split.
  • Management Commentary: Management intends to take all reasonable measures to regain compliance and will monitor the stock price. No specific determination regarding a reverse stock split or other actions has been made at this time.
  • Risks and Contingencies: Failure to regain compliance could result in delisting. Potential negative implications include an adverse effect on stock price, reduced liquidity, loss of federal preemption of state securities laws, and greater difficulty in obtaining financing. There is no assurance that the Company will satisfy the requirements or that an appeal against delisting would be successful.

Investor Verification Checklist

  • Verify the current closing bid price of EKSO stock to assess proximity to the $1.00 threshold.
  • Monitor official announcements for any declaration of a reverse stock split or other capital structure changes.
  • Check the Company's status regarding the "market value of publicly held shares" requirement, which is necessary to qualify for a second compliance period.
  • Review subsequent filings for updates on the appeal process if the initial 180-day period expires without compliance.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.